Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Curvebeam AI Ltd. ( (AU:CVB) ) just unveiled an update.
Curvebeam AI Ltd. reported significant growth in Q1 FY26, with a 33.3% increase in purchase orders for its HiRise™ devices compared to the previous year. The company completed a placement raising A$6.5 million and executed a strategic partnership with Weiying Intelligent Medical Technology for distribution and manufacturing in China. Additionally, Curvebeam AI is advancing its vendor financing facility and aims for FDA clearance of its BMD MDCT software by mid-CY26, positioning itself strongly in the medical imaging market.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
Curvebeam AI Ltd. operates in the medical technology industry, focusing on advanced imaging solutions. The company is known for its HiRise™ devices and WBCT products, with a market focus on orthopedic imaging and diagnostics.
Average Trading Volume: 464,747
Technical Sentiment Signal: Sell
Current Market Cap: A$38.36M
For an in-depth examination of CVB stock, go to TipRanks’ Overview page.